Q-linea AB (publ) (STO:QLINEA)
0.0591
-0.0042 (-6.64%)
Jul 11, 2025, 5:29 PM CET
Q-linea AB Company Description
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom and European Union.
The company offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert.
It also develops Podler, a portable blood culture unit for incubating and detecting growth in blood bottles.
The company serves physicians, hospitals, laboratories, healthcare payers, and the medical profession.
The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.
Q-linea AB (publ)

Country | Sweden |
Founded | 2007 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 94 |
CEO | Stuart Gander |
Contact Details
Address: Dag Hammarskjölds väg 52 A Uppsala, 752 37 Sweden | |
Phone | 46 18 444 3610 |
Website | qlinea.com |
Stock Details
Ticker Symbol | QLINEA |
Exchange | Nasdaq Stockholm |
Fiscal Year | January - December |
Reporting Currency | SEK |
ISIN Number | SE0011527845 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Stuart Gander | Chief Executive Officer |
Anders Ljunggren | Managing Director |
Christer Samuelsson | Chief Financial Officer and IR |
Henrik Jacobson | Chief Operating Officer |
Ulrika Stolpe | HR Manager |
Jonas Melin | Director Product Development |
Thomas Fritz | Chief Commercial Officer |
Victoria Lerneryd | Manager of QA/RA |